iCell Gene Therapeutics
Biotechnology ResearchNew York, United States11-50 Employees
iCell Gene Therapeutics is a clinical-stage biopharmaceutical company developing chimeric antigen receptor (CAR) immunotherapies designed to be innovative, first-in-class and lifesaving. We are focused on developing treatments for diseases where no treatment options exist and where dramatic increases in quality and duration of life are needed, including autoimmune disorders, AML, and T-cell malignancies. We are currently conducting clinical trials in the U.S. and China utilizing our CARvac, T-cell targeted CARs, compound CARs and non-gene edited universal CARs engineered as treatments for autoimmune diseases, cancer, and organ rejections. For more information, please visit http://icellgene.com/
1-888-653-2347 
support@leadiq.com 
